Minutes of Consumer and Patient Working Group meetings

The meeting was held online from 2pm to 4pm.

11 September 2025 interim meeting record [PDF, 154 KB]

Present:

• Malcolm Mulholland (Chair)
• Libby Burgess
• Tim Edmonds
• Chris Higgins
• Francesca Holloway
• Trent Lash
• Gerard Rushton
• Rachel Smalley
• Tracy Tierney
• Deon York

Pharmac staff in attendance:

• Jannel Fisher (Reset Programme Manager)
• Sarona Iosefa (Reset Programme Engagement Lead)
• Sam McCarthy (Reset Programme Project Manager)
• Becky Littlewood (Reset Programme Coordinator)
• Brent McPherson (Manager, Strategic Planning and Performance) 

1.       Karakia and welcome

Opening by the Chair, and whakawhanaungatanga to welcome the Programme Coordinator and Project Manager. 

2.        Minutes of previous meeting

Minutes of the previous meeting minutes were approved.

• Moved by: Libby
• Seconded by: Rachel

3.        Action items

Action register reviewed and completed actions were noted.  

4.        Interest register

No new declarations or changes were made. 

5.       Pharmac Vision

Members engaged in a constructive discussion on the development of a new vision and strategy for Pharmac. Key points included:

• Members emphasised the importance of a vision that is forward-looking, aspirational, and enduring. It should reflect a commitment to improving health and wellbeing and ensuring timely access to treatments and technologies. It must encompass the full scope of Pharmac’s work, including medicines and medical devices.
• While acknowledging budget constraints, members agreed that the vision should not be limited by financial considerations.
• Members noted a strong public desire for meaningful change. They advocated for an outcomes-focused strategy that clearly communicates what will change and how progress will be measured.
• Members recommended revisiting Pharmac’s organisational values to ensure they align with and support the new vision and strategy. They highlighted the influence of values on organisational culture.
• Although the vision and strategy development is primarily an internal exercise, members stressed the importance of an outward-facing approach. They strongly recommended meaningful consumer involvement throughout the process.

The following themes were considered essential to the vision and strategy:

Timely, Certainty, Access, Trust, Respect, Partnership, Integration, Enabler, Excel, Thriving Society, Proactive, Integrity, Authenticity, Transparency, Positivity.

Members requested that a detailed summary of this discussion be shared with Pharmac’s new Chief Executive and Senior Leadership Team to inform their strategic thinking.

Agreed actions: 

• Members to provide any written reflections or notes on the vision and strategy to the Reset Programme team.
• Pharmac to share key insights from the working group discussion with the new Chief Executive and Senior Leadership Team.
• Pharmac to report back to the working group on how consumer input has been incorporated into the development of the vision and strategy.

6.      General Business 

Members reviewed the results of a prioritisation exercise undertaken to inform future actions for the Reset Programme. The discussion focused on:

• The weighting of prioritisation criteria;
• Resource constraints impacting delivery;
• The need to break down the Health Technology Assessment (HTA) process into clear, actionable items.

The Programme Manager noted that the Quarter Two 90-day plan will commence on 1 October, and highlighted the importance of beginning to scope actions. To maintain momentum, the Chair advised he would connect with the Reset Programme Manager and follow up with members via email outlining next steps.

Members inquired about the possibility of another face-to-face meeting in 2025. The Chair advised that, due to scheduling conflicts, no suitable date has been identified. The next in-person meeting is expected to be held in late January 2026, as currently scheduled.

The Chair provided an update on his submission to the Health Select Committee regarding amendments to the Pae Ora legislation, made on behalf of Patient Voice Aotearoa. He clarified that the submission did not reference the Consumer Working Group’s involvement.

Agreed actions: 

• Chair to discuss 90-day plan action with the Reset Programme Manager and to update members on next steps. 

Close of meeting at 4.00pm

Next meeting is 2.00pm – 4.00pm on Thursday 25 September to discuss Pharmac’s communications approach. 

The meeting was held online from 2pm to 3.30pm.

28 August 2025 meeting record [PDF, 130 KB]

Present:

• Malcolm Mulholland (Chair)
• Libby Burgess
• Tim Edmonds
• Chris Higgins
• Francesca Holloway
• Trent Lash
• Gerard Rushton
• Rachel Smalley
• Tracy Tierney
• Deon York

Pharmac staff in attendance:

• Jannel Fisher (Reset Programme Manager)
• Sarona Iosefa (Reset Programme Engagement Lead)

Karakia and welcome

Opening by the Chair

1.        Minutes of previous meeting

Minutes of the previous meeting minutes were approved.

• Moved by: Gerard
• Seconded by: Deon

2.        Action items

Action register reviewed and completed actions were noted.  

Agreed actions:

• Chris Higgins to engage with the Reset Programme team regarding the potential sharing of rare disorder contacts.

3.        Interest register

No new declarations or changes were made. Members requested that the interest register be shared with the working group, which was unanimously supported.

Agreed actions:

• The interest register to be included in future meeting packs.

4.        Future 90-day plan actions

Members discussed the prioritisation of actions for future 90-day plans. Key discussion points included:

• Many actions are interconnected and may span multiple quarters.
• Understanding the planned work to improve Health Technology Assessment (HTA) processes this year is essential to focus efforts effectively.
• The Working Group’s role is to define what “good” looks like and support Pharmac in implementing improvements.
• The 90-day plans must be developed collaboratively with Pharmac to ensure alignment, feasibility, and adequate resourcing.

The group reviewed a list of potential actions, drawn from previous meetings and Pharmac’s planned work. Members agreed to continue refining these actions.

There were mixed views on the usefulness of the proposed prioritisation tool, particularly regarding its assessment of effort and influence. However, it was agreed that the tool provides a useful starting point. Each member will use the tool individually, and results will be discussed collectively.

It was noted that the 90-day planning process is iterative and will be regularly reviewed by the working group.

Agreed actions:

• Pharmac to create a shared document for members to propose additional actions.
• The shared document will include:
  • Intended changes
  • Key considerations
  • Member feedback on the prioritisation tool
• Members to contribute to the shared document by 10pm, Wednesday 3 September.
• Pharmac to distribute the action list and prioritisation tool to members by Thursday 4 September.
• Members to complete the prioritisation exercise by 10pm, Monday 8 September.
• Pharmac to compile the results and present them under General Business at the next meeting on 11 September.

5.        General business

The Working Group inquired whether the advice Pharmac provided to the Minister regarding potential changes to the Pae Ora Act would be proactively released. The Reset Programme Manager advised that the Minister requires time to consider the advice. It will be shared with members as soon as it is appropriate to do so.

The Medicines Strategy was discussed. Members agreed that this matter should be progressed independently by their respective communities, outside of the Pharmac work programme.

Members discussed the importance of ensuring Pharmac’s performance measures reflect the patient voice. The Reset Programme Manager advised that the upcoming discussion on Pharmac’s Vision and Strategic Priorities at the next meeting would be the appropriate forum to explore this further.

6.        Meeting key messages

Members are encouraged to engage with their wider networks to discuss the proposed future action items and the prioritisation tool.

Close of meeting at 3.30pm

Next meeting is 2.00pm – 4.00pm on Thursday 11 September to discuss Pharmac’s vision.

The meeting was held online from 2pm to 4.10pm. 

14 August 2025 meeting minute [PDF, 111 KB]

Present:

Rachel Smalley (Deputy Chair)

Libby Burgess

Tim Edmonds

Chris Higgins

Francesca Holloway

Trent Lash

Gerard Rushton

Tracy Tierney

Deon York 

Pharmac staff in attendance:

Jannel Fisher (Reset Programme Manager)

Michael Johnson (Director Strategy, Policy and Performance)

Sarona Iosefa (Reset Programme Engagement Lead)

External attendees:

Jess Hewat (Treasury Manager, Health & ACC) 

Apologies:

Malcolm Mulholland (Chair) 

1. Karakia and welcome

Opening by the Deputy Chair 

2. Minutes of previous meeting

Minutes of the previous meeting minutes were approved.

• Moved by: Rachel
• Seconded by: Gerard

3. Action items

Reset Programme Manager gave an update on completed and active actions. The group discussed the consumer network database and the best way to support this action.

Agreed actions:

• Pharmac to create a shared consumer network database document for member input.

4. Interest register

No new declarations or changes were made.

5. Budget 2026/27 discussion

The group discussed the Budget process, including key timeframes and the use of Treasury templates.

Director of Strategy, Policy and Performance provided an update on the current work underway for Budget 2026/27. He noted the Minister’s expectation that individual medicines should not be included in the bid.

Manager for Health & ACC at Treasury explained that the templated approach ensures consistency and helps manage the volume of Budget bids. She acknowledged that while templates are essential, additional conversations and supporting information –such as those provided by Pharmac – are also important. She emphasised that the Budget process and bids must align with the Government’s fiscal strategy.

Members expressed frustration at their limited influence in the process, particularly regarding input into the Budget Policy Statement. Concerns were raised about the achievability of Pharmac’s Letter of Expectations, considering recent unsuccessful Budget bids.

Members sought clarification on whether Treasury consider New Zealand’s medicines spend comparative to other countries, and how equity and severity of need is considered. 

Suggestions from members to strengthen future Budget bids included:

• Using aggregate data to demonstrate impact and value
• Emphasising patient outcomes
• Reframing the relationship team bid to highlight the benefits of engagement.

Members also discussed the importance of aligning consumer voices and illustrating the human impact of investing in medicines.

Agreed actions:

• Rachel, Francesca, Tracy, and Deon to co-develop an approach to tell the human impact of medicine investment.
• Pharmac to report back to the working group on how aggregate data and patient outcomes can be effectively incorporated into the 2026/27 Budget bid.

6. General business

• The draft Pae Ora advice document, prepared by members for inclusion in Pharmac’s advice to the Minister, was reviewed and discussed.
• Members noted the need to balance aspirational goals with operational feasibility, ensuring the proposed changes are future proofed.
• The urgency to finalise the advice and secure majority agreement was acknowledged, with further discussions required to refine the document.
• The contributions of Chris, Libby, and Tim in preparing the draft were acknowledged and appreciated.

Agreed action:

• The Chair will lead the finalisation of the Pae Ora advice document in collaboration with members and submit the final version to Pharmac by Monday, 18 August.

Close of meeting at 4.10pm.

Next meeting is 2.00pm–4.00pm on Thursday 28 August to discuss future 90-day plan action items.

 

 

 

The meeting was held online from 9am to 11am.  

30 July 2025 meeting minute [PDF, 135 KB]

Present:

• Dr Malcolm Mulholland (Chair)
• Tim Edmonds
• Chris Higgins
• Francesca Holloway
• Gerard Rushton
• Rachel Smalley (Deputy Chair)
• Tracy Tierney
• Deon York

Pharmac staff in attendance

• Jannel Fisher (Reset Programme Manager)
• Michael Johnson (Director Strategy, Policy and Performance)

 Apologies

• Libby Burgess
• Trent Lash

1. Karakia and welcome

Opening by the Chair

2. Minutes of previous meeting

Minutes of the previous meeting minutes were approved.

• Moved by: Tracy
• Seconded by: Francesca

3. Interest register

Updates and declarations were noted.

4. Pae Ora legislation discussion

The group discussed potential amendments to the Pae Ora (Healthy Futures) Act 2022 and the advice to be provided to Associate Minister of Health, Minister Seymour.

Director Strategy, Policy and Performance confirmed that:

• Changes to Pharmac legislation can be introduced at the Health Select Committee stage
• Pharmac provides advice to Ministers and the Ministry of Health but will not at this time submit directly to the Health Select Committee.
• Minister Brown is the Minister responsible for the Pae Ora legislation.

Concerns were raised by members about the phrase “from within the available funds” in Pharmac’s statutory objective. Some members viewed it as an unnecessary constraint and misaligned with patient and consumer expectations. Others noted that budget references are inconsistent with other government agencies and already required under the Crown Entities Act and Public Finance Act.

Members discussed potential unintended consequences of removing the phrase, including its impact on commercial negotiations and government accountability. While Pharmac’s ability to seek out-of-cycle funding was acknowledged, concerns were raised that current budget bids cannot reflect patient and system-level impact and may disadvantage Pharmac.  

The group emphasised the need for statutory objectives to be enabling and future-focused to support the 5-year reform. Members saw an opportunity to strengthen the objectives to reflect a whole-of-system approach, allowing for budget bids that demonstrate broader fiscal and societal benefits. It was also noted that the HTA framework is fundamental and there was disappointment that the budget bid to support this work was unsuccessful.

Additional suggestions for statutory objective changes included:

• Emphasising innovation and timely access
• Including societal and fiscal impacts
• Strengthening equity language
• Changing language from pharmaceuticals to medical products

The Director of Strategy, Policy and Performance proposed that the view of the Working Group be put forward to the Minister Seymour as part of Pharmac’s formal advice. It was discussed that Working Group members should avoid making a submission in their capacity as Pharmac’s Consumer and Patient Working Group, as this could be perceived to be reflecting Pharmac’s position.

Written feedback from Libby and Trent was considered in the discussion.

Motion:

That the Working Group supports the removal of the budget reference in Pharmac’s statutory objective.

• Moved by: Malcolm
• Seconded by: Tim
• Opposed by: Rachel
• Motion carried

Agreed actions:

• Internal Pharmac discussion documents will incorporate feedback from the Working Group.
• Chris, Tim and Libby will draft advice to be included as an appendix to Pharmac’s advice to the Minister.
  • The draft will reflect diverse perspectives (not consensus) and be shared with the Working Group early next week.
  • Final advice to be submitted to Pharmac by 13 August 2025.
• The Working Group will receive a copy of the advice provided to the Minister.
• Members will consider preparing individual submissions and inviting broader consumer representation into these submissions.

General business

• Members unable to attend meetings may provide written feedback, which will be considered during discussions. As conversations may evolve, members are encouraged to follow up with the Chair to discuss meeting outcomes. Written feedback should be circulated to members as early as possible to support informed discussion.
• Members were asked to review the proposed meeting schedule and upcoming discussion topics as a priority. Feedback should be provided to the Reset Programme team to enable timely scheduling of meetings and commissioning of relevant discussion papers.

Agreement on public communications

• It was confirmed that members may share the topic of upcoming meetings with their wider networks and engage in discussion about the subject matter. However, members must not disclose any confidential information shared as part of the Working Group papers or meetings.
• It was confirmed that members, with the support of the Chair and following a ‘no surprises approach’ with the Reset Programme Manager, are welcome to issue public statements about their work. The Pharmac communications team is available to assist with this.

 Close of meeting 10.50am.

The meeting was held in person from 10am to 1pm at the Pharmac offices.  

21 July 2025 meeting minute [PDF, 101 KB]

Present:

• Dr Malcolm Mulholland (Chair)
• Libby Burgess 
• Tim Edmonds
• Chris Higgins
• Francesca Holloway
• Trent Lash (via Teams online) 
• Gerard Rushton
• Tracy Tierney
• Deon York 

Pharmac staff in attendance

• Jannel Fisher (Reset Programme Manager)
• Sarona Iosefa (Reset Programme Engagement Lead)
• Saar Cohen-Ronen (General Counsel, Legal)  

Apologies

• Rachel Smalley (Deputy Chair) 

1. Whakawhanaungatanga

Everyone introduced themselves with a photograph to explain their “why” for being part of the newly formed Consumer and Patient (CAP) working group. 

2. Declarable Interests

General Counsel advised members on how Pharmac records and manages declarable interests. There was a discussion on the multiple roles members have and potential perceived conflicts. General Counsel left the meeting. 

3. Terms of Reference

Discussion about the purpose and scope of the CAP working group and if the three workstreams listed in the terms of reference were broad enough to enable the group to support the wider Pharmac reform. The three workstreams being: (1) strategic vision; (2) enhancing consumer engagement and trust, and (3) better processes. 

It was clarified and agreed that the scope of the CAP working group includes both the formal Reset Programme, and the wider reform of Pharmac. This aligns with the recommendations of the Prendergast Report. 

Reset Programme Manager advised how the 12-month reset would inform and influence the future 4-year improvement programme.  

Motion: 

A motion was moved that the CAP working group approves the terms of reference with the agreed changes and to publish them. There was unanimous agreement (yes). 

Agreed actions:

• Remove reference to the CAP working group not being involved in the operations of Pharmac in the terms of reference. 
• Insert reference to supporting the wider Pharmac reform in the purpose and scope sections of the terms of reference.  
• Remove sub-bullet points under the three workstreams in the scope section of the terms of reference.  
• Change name of group to the Consumer and Patient Working Group to reflect wide makeup and representation of the group.
• Publish the updated terms of reference on the Pharmac website [PDF, 143 KB]. 

4. Reset Programme Approach

Discussion about the roles and responsibilities of the CAP working group, including decision making for the reset programme. It was noted that the CAP working group Chair is part of the reset programme governance group.  

Members also discussed the role of the CAP working group and Pharmac’s existing Consumer Advisory Committee (CAC). Concern was raised about work being duplicated or the two groups working at cross purposes.  

Members noted that Pharmac can’t shy away from the “too hard” items and that while some of this work may not be delivered in the reset programme it needs to be considered for the future 4-year improvement programme.   

Motion:

Reset programme approach paper was noted by members as background information.  

Agreed actions:

• Update the roles and responsibilities table so the CAP working group is “consulted” not “informed” on decision making.
• As action items for the reset programme are scoped, provide clarity on the role and responsibilities of the CAP working group and CAC.  
• Capture action items that could form part of the future 4-year improvement programme.  

5. First 90-Day Plan

Reset Programme Manager presented the draft first 90-day plan. The actions are based 
on recommendations from the consumer engagement workshop report and focus 
building trust with consumers and quick wins. 

Agreed actions:

1. Establish consumer working group to support the reset programme
2. Formalise consumer network to support wider consumer input
3. Expand Pharmac’s engagement function to strengthen consumer relationships
4. Publish an update on progress with the Pharmac Review recommendations
5. Provide advice on the 2026/27 budget bid
6. Provide advice on the Pae Ora legislation amendment
7. Develop a joined-up communications planning approach
8. Clinical meeting recommendations. 

Discussion about progress with last year’s Pharmac Letter of Expectations and previous review recommendations, measuring progress and impact of each action, and advocating for change outside the role of the CAP working group.  

Members prioritised which of these actions they wanted to focus on first. Members agreed the first five to focus on working with Pharmac on were:  

1. Provide advice on the Pae Ora legislation amendment 
2. Provide advice on the 2026/27 budget bid 
3. Progress on the Pharmac Review recommendations and 2024/25 Pharmac Letter of Expectations  
4. Clinical meeting recommendations 
5. Develop a joined-up communications planning approach. 

Reset Programme Manager spoke about the importance of defining the problem to then work on designing the solution together, which was supported and reinforced by the Chair.  

Motion:  

A motion was moved that the CAP working group accepts the 90-Day Plan approach. There was unanimous agreement (yes). 

Agreed actions:

• The next CAP working group meeting to focus on the Pae Ora legislation, including previous advice and timeframes for current amendments.  
• Members to provide the reset programme team with key contacts to start forming the consumer network database.  
• Regular reflection time scheduled into meetings to enable frank discussions on achievements so far, and value add as a group. 

6. Meeting approach

Members agreed to begin with fortnightly meetings to make progress on the action plan, but it was noted the frequency may reduce in the future. Members agreed to use subgroups, as needed, to address specialist issues and to meet timeframes. Members also asked for quarterly face to face meetings to be considered.  

Discussion about what information can be shared prior to meetings and following meetings with wider networks. Members requested that meeting minutes be provided as quickly as possible rather than waiting for the next meeting.  

Motion:

A motion was moved that the CAP working group accepts the proposed meeting approach. There was unanimous agreement (yes). 

Agreed actions:

• Poll to be sent out to members to confirm future online meeting dates, before the dates for face-to-face meetings are confirmed.
• Meeting papers to note if they can be discussed with wider networks prior to the meeting
• Add agenda item to agree what can be shared from the meeting and what is released publicly
• Draft minutes to be provided to members within three days of the meeting and members to review and approve minutes within three days of receiving them, before Chair approves release publicly on Pharmac website.
• Future meeting packs to have page numbers and Pharmac details on page one. 

Close of meeting 1pm.